CBIZ Investment Advisory Services LLC Has $71,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

CBIZ Investment Advisory Services LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 163.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 587 shares of the biotechnology company’s stock after acquiring an additional 364 shares during the quarter. CBIZ Investment Advisory Services LLC’s holdings in Sarepta Therapeutics were worth $71,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Manchester Capital Management LLC grew its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. grew its stake in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank raised its holdings in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth $36,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock opened at $97.19 on Friday. The stock has a 50-day moving average price of $111.73 and a two-hundred day moving average price of $119.96. Sarepta Therapeutics, Inc. has a 1 year low of $97.06 and a 1 year high of $173.25. The stock has a market cap of $9.43 billion, a PE ratio of 77.75 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on SRPT shares. HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Scotiabank assumed coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price for the company. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, Royal Bank of Canada reduced their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.